The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Why & How Our Biologic Drug Discussion with Patients Should Evolve

Why & How Our Biologic Drug Discussion with Patients Should Evolve

February 17, 2019 • By Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
WindNight / shutterstock.com

WindNight / shutterstock.com

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on gold, penicillamine and those “cancer” drugs, methotrexate and azathioprine, are so enamored of the current therapeutic era. Not only has it fostered a genuine sense of control over the autoimmune chaos confronting our patients for the first time, the risks also appear relatively modest.

You Might Also Like
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents
Explore This Issue
February 2019

The same tensions felt long ago about infection and cancer when adopting conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) arose again in our collective psyche as we entered the biologic age. As before, the preponderance of positive experiences has begun to allay our reservations. Notwithstanding comorbidities or histories that might put the individual in front of us at extra risk, we proceed more confidently. Nonetheless, our speeches to patients and the related media they encounter remain heavy on the risks. It may be time for modification.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background

In recent years, the aggregation of our clinical experience and real-world evidence reveals a growing ambiguity between the boxed warnings for biologic agents and information not factored into the warnings. The admonitions for the biologic and small molecules we use are similar and class based, with little deviation from the initial versions exemplified by that for infliximab in 1998:1 “Patients treated with Remicade (infliximab) are at increased risk for developing serious infections that may lead to hospitalization or death.”

Increased? Compared to what? In most randomized, controlled trials of biologic agents for rheumatic disorders, the cohort receiving the investigational biologic agent has a few percent higher reported serious infections than do controls. Occasionally, the reverse is true. The differences cited in serious infection rates between the comparator arm for anti-tumor necrosis factor (TNF) class drugs (infliximab, adalimumab and etanercept) are not statistically significant.2,3 Nonetheless, for adverse events considered serious or life-threatening, even insignificant differences between active and comparator arms elicit these boxed warnings.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Even if the warnings are a bit overblown, we are okay with that. A multitude of non-rheumatology healthcare workers will encounter our patients on biologic agents in a variety of settings and should be sharply alerted to the potential that a patient may be less able to confront an infection without assistance. The trap lies in the reflexive attribution of every microbial encounter to the drug rather than considering other aspects of the patient’s life condition.

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Biologics & Biosimilars, Research Reviews, Rheumatoid Arthritis Tagged With: Opinion, Speak Out RheumatologyIssue: February 2019

You Might Also Like:
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents
  • Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)